{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-042812","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2026-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.645742+00:00","generated_at":"2026-05-16T03:50:16.102592+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Enanta Q1 FY2026 net loss $11.9M ($0.42/sh); pipeline advances with zelicapavir and new immunology programs","bullets":["Revenue of $18.6M from AbbVie royalties, up 9% vs $17.0M YoY; net loss narrowed to $11.9M from $22.3M.","Cash & securities $241.9M; runway expected into fiscal 2029.","Zelicapavir Phase 2b RSVHR showed 6.7-day improvement in symptom resolution for high-risk adults; Phase 3 enabling activities ongoing.","New MRGPRX2 immunology program introduced; development candidate selection expected in 2H 2026.","EDP-978 (oral KIT) IND on track for Q1 2026; EPS-3903 (oral STAT6) IND targeting 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-042812","json":"https://secwatch.observer/filing/0001193125-26-042812.json","markdown":"https://secwatch.observer/filing/0001193125-26-042812.md","text":"https://secwatch.observer/filing/0001193125-26-042812.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526042812/0001193125-26-042812-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526042812/enta-20260209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:50:16.102592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}